Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Cancers|May 28, 2022
Gold Glyconanoparticles Combined with 91-99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder TumorsHector Terán-Navarro, Andrea Zeoli, David Salines-Cuevas, et al.
Cancers|June 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial CarcinomaNataliya Mar, Yousef Zakharia, Alejandro Falcon, et al.
European Urology Open Science|April 27, 2023
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
Frontiers in Oncology|May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinomaMartin Zarba, Dylan O'Sullivan, David Maj, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 13, 2025
Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)Marta Sotelo, Mireia Pelaez, Laura Basterretxea, et al.
European Urology Focus|November 10, 2020
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract CarcinomaJens Bedke, Axel S Merseburger, Yohann Loriot, et al.
European Urology|March 27, 2019
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary TractCora N Sternberg, Yohann Loriot, Nicholas James, et al.
The New England Journal of Medicine|July 25, 2019
Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaYohann Loriot, Andrea Necchi, Se Hoon Park, et al.
The Lancet. Oncology|January 14, 2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 studyArlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, et al.
BMC Cancer|November 3, 2023
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 studyDo-Youn Oh, Maria Alsina Maqueda, David I Quinn, et al.
Pageof 9